Series 3: When the Orphan Drug Act Came Back to Congress in 1992.

The Orphan Drug Act of 1983 exists for one reason: Congress recognized that rare diseases face structural barriers to traditional drug development.

Not scientific failure.
Structural reality.

From the Act’s findings and purpose (faithfully paraphrased):

Because so few individuals are affected by any one rare disease, pharmaceutical companies are often unwilling to develop drugs for such diseases, even though such drugs may be medically necessary.

The law was explicit:
Rarity, feasibility limits, and unavoidable uncertainty were never supposed to eliminate opportunity.

They were the starting conditions.

The Orphan Drug Act returned to Congress in 1992.

Not because it failed.
But because it worked.

Several orphan drugs had succeeded.
Some were profitable.
And critics began asking whether incentives were too generous.

What’s critical — and often forgotten — is what Congress debated and what it did not.

Congress revisited:

• Economic guardrails

• Exclusivity definitions

• Market behavior concerns

Congress did not revisit:

• Acceptance of small trials

• Acceptance of heterogeneity

• Acceptance of long timelines

• Acceptance of uncertainty

There was no moment where Congress said:
“Rare diseases now need certainty.”

They reaffirmed the framework — and adjusted economics, not science.

The Word That Shows Up in Every Rare Disease Room

One word appears in nearly every rare-disease meeting:

Uncertainty.

It’s usually said carefully.
Sometimes apologetically.
Often as if it ends the discussion.

But for rare patients, uncertainty is not a flaw.

It is the environment.

Why Uncertainty Is Inevitable in Rare Disease

Rare diseases are rare because:

• Patient populations are small

• Disease courses vary

• Progression is uneven

• Outcomes may take years to fully reveal

This means:

• Datasets will be limited

• Signals may be noisy

• Effects may be modest but meaningful

• Perfect clarity may never arrive

None of this reflects bad science.

It reflects reality — the reality Congress acknowledged when it passed the Orphan Drug Act.

When Uncertainty Stops Being Context

In theory, uncertainty is something to be weighed.

In practice, rare patients increasingly see uncertainty treated as:

• A reason to delay

• A reason to demand more data

• A reason to wait for clarity that may never come

When that happens, uncertainty quietly shifts from context to disqualifier.

For rare diseases, that shift is often fatal to development.

Managing vs. Eliminating Uncertainty

There is a critical distinction:

• Managing uncertainty means acknowledging limits and making decisions anyway

• Eliminating uncertainty means waiting until doubt disappears

For common diseases, waiting may be possible.

For rare diseases, waiting often means:

• The trial cannot be repeated

• Patients progress or die

• Sponsors withdraw

• Programs collapse

At that point, uncertainty doesn’t get resolved.

It becomes irrelevant — because there is nothing left to study.

Why Patients Experience Uncertainty Differently

Patients with rare diseases already live with uncertainty every day:

• Will symptoms worsen?

• Will independence be lost?

• Will time run out before help arrives?

So the real question for patients isn’t:

“Is there uncertainty?”

It’s:

“Is this uncertainty worth the chance to slow harm?”

That is not desperation.
It is a rational, ethical calculation.

When Uncertainty Is Treated as Failure

This is how rare-disease development quietly breaks down.

When uncertainty is treated as proof that something doesn’t work:

• Programs stall

• Sponsors retreat

• Patients are left with nothing

Not because a therapy failed —
but because certainty could not be achieved.

This is the rare-disease version of a Type II error:
a potentially helpful therapy rejected not because it failed,
but because it could not be proven enough.

Rare & Relentless Takeaway

Uncertainty is not a bug in rare-disease development.
It is the environment.

The real question is not whether uncertainty exists —
but whether it is managed responsibly or used as a reason to stop.

For rare patients:

• Waiting is not neutral

• Delay is not harmless

• Uncertainty is not theoretical

It feels like time slipping away.

Patient & Foundation Checklist

When “Uncertainty” Is Raised in FDA Engagement

1. Reality Check
☐ Is the disease rare or ultra-rare?
☐ Is the population small and heterogeneous?
☐ Is long-term data slow or difficult to generate?

If yes, uncertainty is structural — not a flaw.

2. How Is Uncertainty Being Treated?
☐ Is it acknowledged as expected?
☐ Is it weighed in benefit–risk discussions?
☐ Or used to delay or stop?

🚩 Red flag: Uncertainty framed only as a problem, never as context.

3. Feasibility vs. Perfection
☐ Are trial-size limits acknowledged?
☐ Is it recognized that certainty may never be eliminated?
☐ Is feasibility shaping expectations early?

4. Impact of Delay
☐ Is patient harm from delay acknowledged?
☐ Is program viability discussed?
☐ Is time treated as neutral?

5. Documentation
☐ Is uncertainty documented in meeting notes?
☐ Is feasibility documented alongside it?
☐ Is there clarity on how decisions will be made despite uncertainty?

What Patients & Advocates Can Say Out Loud

You don’t need legal language.
You don’t need to argue statistics.

Use grounding statements like:

• “We understand uncertainty is expected in a disease like this.”

• “Can we talk about how uncertainty is weighed, not just whether it exists?”

• “Given the size of this community, how realistic is it to expect uncertainty to disappear?”

• “From a patient perspective, delay has consequences. How is that being considered?”

• “What level of uncertainty is considered acceptable here?”

• “Can we document how uncertainty will be handled moving forward?”

One grounding line if needed:

“For rare patients, uncertainty is something we already live with. The question is whether it’s managed — or used as a reason to stop.”

Rare & Relentless Reminder

The Orphan Drug Act exists because Congress understood that rare diseases cannot wait for perfect certainty.

When uncertainty is managed:

• Learning continues

• Time is preserved

• Patients have a chance

When uncertainty is treated as disqualifying:

• Programs stall

• Opportunities disappear

• Patients are left with certainty of harm

Next — Series 4 of 9

How Patient Experience Became Evidence — and Why It Still Has to Fight for Its Place